Cytokine Signaling in Tumor Progression

키워드

참고문헌 (86)

1. Mantovani A, "Cancer-related inflammation", Nature, 454, pp.436~444 (2008)
2. O'Shea JJ, "JAKs and STATs in immunity, immunodeficiency, and cancer", N Engl J Med, 368, pp.161~170 (2013)
3. Spangler JB, "Insights into cytokine-receptor interactions from cytokine engineering", Annu Rev Immunol, 33, pp.139~167 (2015)
4. Kisseleva T, "Signaling through the JAK", STAT pathway, recent advances and future challenges, 2002, pp.285, 1~24
5. Rane SG, "Janus kinases: components of multiple signaling pathways", Oncogene, 19, pp.5662~5679 (2000)
6. Vainchenker W, "JAK", STAT signaling in hematological malignancies, 2013, pp.32, 2601~2613
7. Woellner C, "The hyper IgE syndrome and mutations in TYK2", Immunity, 26, pp.535~536 (2007)
8. Kralovics R, "A gain-of-function mutation of JAK2 in myeloproliferative disorders", N Engl J Med, 352, pp.1779~1790 (2005)
9. Casanova JL, "Inborn errors of human JAKs and STATs", Immunity, 36, pp.515~528 (2012)
10. O'Shea JJ, "The JAK-STAT pathway : impact on human disease and therapeutic intervention", Annu Rev Med, 66, pp.311~328 (2015)
11. Durant L, "Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis", Immunity, 32, pp.605~615 (2010)
12. Leonard WJ, "Jaks and STATs: biological implications", Annu Rev Immunol, 16, pp.293~322 (1998)
13. 김지성, "Cell-based Immunotherapy for Colorectal Cancer with Cytokine-induced Killer Cells", Immune Network, 16(2), pp.99~108 (2016), 대한면역학회[DOI]
14. Irie-Sasaki J, "CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling", Nature, 409, pp.349~354 (2001)
15. David M, "Differential regulation of the alpha", beta interferon-stimulated Jak, Mol Cell Biol, pp.1995, 15[DOI]
16. Constantinescu SN, "Mining for JAK-STAT mutations in cancer", Trends Biochem Sci, 33, pp.122~131 (2008)
17. Clark JD, "Discovery and development of Janus kinase(JAK)inhibitors for inflammatory diseases", J Med Chem, 57, pp.5023~5038 (2014)
18. Yu H, "The STATs of cancer--new molecular targets come of age", Nat Rev Cancer, 4, pp.97~105 (2004)
19. Bandaranayake RM, "Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F", Nat Struct Mol Biol, 19, pp.754~759 (2012)
20. Geron I, "Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors", Cancer Cell, 13, pp.321~330 (2008)
21. Tefferi A., "JAK and MPL mutations in myeloid malignancies", Leuk Lymphoma, 49, pp.388~397 (2008)
22. Staerk J, "The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective", JAK-STAT, 1, pp.184~190 (2012)
23. Stein BL, "Disease burden at the progenitor level is a feature of primary myelofibrosis : a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients", Exp Hematol, 39, pp.95~101 (2011)
24. Steensma DP, "The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both"atypical"myeloproliferative disorders and myelodysplastic syndromes", Blood, 106, pp.1207~1209 (2005)
25. Kralovics R, "Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders", Blood, 108, pp.1377~1380 (2006)
26. Pietra D, "Somatic mutations of JAK2 exon 12 in patients with JAK2(V617F)-negative myeloproliferative disorders", Blood, 111, pp.1686~1689 (2008)
27. Lippert E, "The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera", Blood, 108, pp.1865~1867 (2006)
28. Kilpivaara O, "A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms", Nat Genet, 41, pp.455~459 (2009)
29. Villeval JL, "New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients", Semin Thromb Hemost, 32, pp.341~351 (2006)
30. Jeong EG, "Absence of JAK2 exon 12 mutation in acute leukemias", Acta Haematol, 119, pp.38~39 (2008)
31. Jeong EG, "Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers", Clin Cancer Res, 14, pp.3716~3721 (2008)
32. dos Santos NR, "Pre-TCR expression cooperates with TEL-JAK2 to transform immature thymocytes and induce T-cell leukemia", Blood, 109, pp.3972~3981 (2007)
33. Kennedy JA, "Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo", Proc Natl Acad Sci USA, 103, pp.16930~16935 (2006)
34. Roncero AM, "Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development", Leukemia, 30, pp.94~103 (2016)
35. Schwaller J, "Stat5 is essential for the myelo-and lymphoproliferative disease induced by TEL", JAK2, 2000, pp.6, 693~704
36. Monni R, "The TEL-Jak2 oncoprotein induces Socs1 expression and altered cytokine response in Ba", F3 cells, 2001, pp.20, 849~858
37. dos Santos NR, "A transgenic mouse model for TEL-JAK2-induced B-cell lymphoma", leukemia, 2006, pp.20, 182~185
38. Onnebo SM, "Alternative TEL-JAK2 fusions associated with T-cell acute lymphoblastic leukemia and atypical chronic myelogenous leukemia dissected in zebrafish", Haematologica, 97, pp.1895~1903 (2012)
39. Cramer K, "BCR", ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair, 2008, pp.68, 6884~6888
40. Dierov J, "TEL", platelet-derived growth factor receptor beta activates phosphatidylinositol 3(PI3)kinase and requires PI3 kinase to regulate the cell cycle, 2002, pp.99, 1758~1765
41. Yokota A, "Constitutively active ABL family kinases, TEL", ABL and TEL, Leukemia, pp.2017[DOI]
42. Shain KH, "Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells : implications for microenvironment influence on tumor survival and proliferation", Cancer Res, 69, pp.1009~1015 (2009)
43. Chatterjee M, "Combined disruption of both the MEK", ERK and the IL-6R, Blood, pp.2004, 104[DOI]
44. Ranger JJ, "Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression", Cancer Res, 69, pp.6823~6830 (2009)
45. Liu F, "Upregulation of MEK5 by Stat3 promotes breast cancer cell invasion and metastasis", Oncol Rep, 37, pp.83~90 (2017)
46. Dhir R, "Stat3 activation in prostatic carcinomas", Prostate, 51, pp.241~246 (2002)
47. Grandis JR, "Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo", Proc Natl Acad Sci USA, 97, pp.4227~4232 (2000)
48. Hang D, "Effects of potentially functional polymorphisms in suppressor of cytokine signaling 3(SOCS3)on the risk of head and neck squamous cancer", J Oral Pathol Med (2016)
49. Concha-Benavente F, "Identification of the cell-intrinsic and-extrinsic pathways downstream of EGFR and IFNγ that induce pd-l1 expression in head and neck cancer", Cancer Res, 76, pp.1031~1043 (2016)
50. Masuda M, "Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma", Cancer Res, 62, pp.3351~3355 (2002)
51. Steelman LS, "Contributions of the Raf", MEK, PTEN, pp.Akt, mTOR and Jak[DOI]
52. Limnander A, "Abl oncogene bypasses normal regulation of Jak", STAT activation, 2004, pp.3, 1486~1488
53. Zhang M, "Selective targeting of JAK", STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia, 2015, pp.112, 12480~12485
54. Wen R, "Jak3 selectively regulates Bax and Bcl-2 expression to promote T-cell development", Mol Cell Biol, 21, pp.678~689 (2001)
55. DeNardo DG, "CD4(+)T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages", Cancer Cell, 16, pp.91~102 (2009)
56. Telliez JB, "Discovery of a JAK3-selective inhibitor : functional differentiation of jak3-selective inhibition over pan-JAK or JAK1-selective inhibition", ACS Chem Biol, 11, pp.3442~3451 (2016)
57. Narla RK, "4-(3′-Bromo-4'hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells", Clin Cancer Res, 4, pp.1405~1414 (1998)
58. Zhang H, "WHI-P154 enhances the chemotherapeutic effect of anticancer agents in ABCG2-overexpressing cells", Cancer Sci, 105, pp.1071~1078 (2014)
59. Linwong W, "Inhibition of the antigen-induced activation of rodent mast cells by putative Janus kinase 3 inhibitors WHI-P131 and WHI-P154 in a Janus kinase 3-independent manner", Br J Pharmacol, 145, pp.818~828 (2005)
60. Changelian PS, "The specificity of JAK3 kinase inhibitors", Blood, 111, pp.2155~2157 (2008)
61. Stepkowski SM, "Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin", Blood, 99, pp.680~689 (2002)
62. Rashid S, "Inhibition of Janus kinases by tyrosine phosphorylation inhibitor, Tyrphostin AG-490", J Biomol Struct Dyn, 33, pp.2368~2379 (2015)
63. Sewgobind VD, "The Jak inhibitor CP-690,550 preserves the function of CD4CD25FoxP3 regulatory T cells and inhibits effector T cells", Am J Transplant, 10, pp.1785~1795 (2010)
64. Ju W, "CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM", TSP, 2011, pp.117, 1938~1946
65. Hart S, "Pacritinib (SB1518), a JAK2", FLT3 inhibitor for the treatment of acute myeloid leukemia, 2011, pp.1, e44~
66. Verstovsek S, "Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor", Leuk Res, 38, pp.316~322 (2014)
67. McCarthy AA, "Exelixis: integrated drug-discovery and development platform for human therapeutics", Chem Biol, 12, pp.407~408 (2005)
68. Moran N, "Incyte comes of age with JAK inhibitor approval", Nat Biotechnol, 30, pp.3~5 (2012)
69. Pardanani A, "Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis", J Clin Oncol, 29, pp.789~796 (2011)
70. Hexner EO, "Lestaurtinib(CEP701)is a JAK2 inhibitor that suppresses JAK2", STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders, 2008, pp.111, 5663~5671
71. Verstovsek S, "Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis", N Engl J Med, 363, pp.1117~1127 (2010)
72. Shi JG, "The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib(INCB018424 phosphate)in healthy volunteers", J Clin Pharmacol, 52, pp.809~818 (2012)
73. Aubert L, "NGF-induced TrkA", CD44 association is involved in tumor aggressiveness and resistance to lestaurtinib, 2015, pp.6, 9807~9819
74. Knapper S, "A phase 2 trial of the FLT3 inhibitor lestaurtinib(CEP701)as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy", Blood, 108, pp.3262~3270 (2006)
75. Hexner EO, "Phase I dose escalation study of lestaurtinib in patients with myelofibrosis", Leuk Lymphoma, 56, pp.2543~2551 (2015)
76. Minturn JE, "Phase I trial of lestaurtinib for children with refractory neuroblastoma : a new approaches to neuroblastoma therapy consortium study", Cancer Chemother Pharmacol, 68, pp.1057~1065 (2011)
77. Diaz T, "Lestaurtinib inhibition of the Jak", STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis, 2011, pp.6, e18856~
78. Soderquist C, "Coexistent BCR-ABL1 and JAK2 V617F : converting CML dwarves to ET staghorns with imatinib therapy", Blood, 124, pp.2463~ (2014)
79. Qian XL, "Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP)", PLoS One, 12, pp.e0171169~ (2017)
80. Zhou A, "Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib", Blood Cancer J, 5, pp.e351~ (2015)
81. Lang L, "FDA approves sorafenib for patients with inoperable liver cancer", Gastroenterology, 134, pp.379~ (2008)
82. Rahmani M, "Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process", Blood, 119, pp.6089~6098 (2012)
83. Huynh H, "Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma", Curr Cancer Drug Targets, 9, pp.738~747 (2009)
84. Yang F, "Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways", Mol Cancer Res, 8, pp.35~45 (2010)
85. Finke J, "MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy", Int Immunopharmacol, 11, pp.856~861 (2011)
86. Adotevi O, "A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients", J Immunother, 33, pp.991~998 (2010)

관련 논문AI추천